{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T12:57:30Z","timestamp":1781701050132,"version":"3.54.5"},"reference-count":21,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003921","name":"Australian Government Department of Health Disability and Ageing","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003747","name":"Department of Health, State Government of Victoria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003747","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jiph.2026.103247","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:06:05Z","timestamp":1777932365000},"page":"103247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Measuring oral COVID-19 antiviral effectiveness using linked Australian data: Challenges and opportunities"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4516-4127","authenticated-orcid":false,"given":"Parveen","family":"Fathima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5678-6677","authenticated-orcid":false,"given":"Anish","family":"Scaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Stepien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen C.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3984-6017","authenticated-orcid":false,"given":"Laura J.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6267-7055","authenticated-orcid":false,"given":"Elizabeth J.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2843-3525","authenticated-orcid":false,"given":"Caroline","family":"Sumpton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2161-9366","authenticated-orcid":false,"given":"Janaki","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bette","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiph.2026.103247_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173644","article-title":"Treatment for COVID-19: an overview","volume":"889","author":"Stasi","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jiph.2026.103247_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1125246","article-title":"The development of COVID-19 treatment","volume":"14","author":"Yuan","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jiph.2026.103247_bib3","unstructured":"The Pharmaceutical Benefits Scheme. Lagevrio\u00ae (molnupiravir) PBS listing 2022 [cited 27 November 2025] Available from: \u3008https:\/\/www.pbs.gov.au\/info\/news\/2022\/03\/lagevrio-molnupiravir-pbs-listing\u3009]."},{"key":"10.1016\/j.jiph.2026.103247_bib4","unstructured":"The Pharmaceutical Benefits Scheme. Paxlovid\u00ae (nirmatrelvir and ritonavir) PBS listing. 2022 [cited 27 November 2025] Available from: \u3008https:\/\/www.pbs.gov.au\/info\/news\/2022\/04\/paxlovid-nirmatrelvir-and-ritonavir-pbs-listing\u3009]."},{"key":"10.1016\/j.jiph.2026.103247_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105768","article-title":"Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: systematic review and network meta-analysis","volume":"221","author":"Zur","year":"2024","journal-title":"Antivir Res"},{"issue":"9","key":"10.1016\/j.jiph.2026.103247_bib6","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S1473-3099(25)00093-3","article-title":"Molnupiravir or nirmatrelvir-ritonavir versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"25","author":"RECOVERY Collaborative Group","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiph.2026.103247_bib7","article-title":"Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study","volume":"33","author":"Liu","year":"2023","journal-title":"Lancet Reg HealthWest Pac"},{"key":"10.1016\/j.jiph.2026.103247_bib8","article-title":"Effectiveness of community-based oral antiviral treatments against severe COVID-19 outcomes in people 70 years and over in Victoria, Australia, 2022: an observational study","volume":"41","author":"Van Heer","year":"2023","journal-title":"Lancet Reg HealthWest Pac"},{"issue":"6","key":"10.1016\/j.jiph.2026.103247_bib9","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s40121-024-00976-5","article-title":"Molnupiravir use among patients with COVID-19 in real-world settings: a systematic literature review","volume":"13","author":"Richmond DiBello","year":"2024","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jiph.2026.103247_bib10","series-title":"National, state and territory population","author":"Australian Bureau of Statistics","year":"2025"},{"key":"10.1016\/j.jiph.2026.103247_bib11","series-title":"Australian immunisation register link to the person level integrated data asset","author":"Department of Health and Aged Care","year":"2024"},{"key":"10.1016\/j.jiph.2026.103247_bib12","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1186\/s12879-026-12536-y","article-title":"Patterns of use of oral antivirals for COVID-19 in people 70 years and over in Victoria, Australia: a linked data study","volume":"26","author":"Edwards","year":"2026","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jiph.2026.103247_bib13","article-title":"Effectiveness of COVID-19 vaccination against COVID-19 specific and all-cause mortality in older Australians: a population based study","volume":"40","author":"Liu","year":"2023","journal-title":"Lancet Reg HealthWest Pac"},{"issue":"4","key":"10.1016\/j.jiph.2026.103247_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-021122","article-title":"The validity of the Rx-Risk comorbidity index using medicines mapped to the anatomical therapeutic chemical (ATC) classification system","volume":"8","author":"Pratt","year":"2018","journal-title":"BMJ Open"},{"issue":"9","key":"10.1016\/j.jiph.2026.103247_bib15","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/jac\/dkae163","article-title":"Effectiveness of nirmatrelvir\/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies","volume":"79","author":"Mesfin","year":"2024","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.jiph.2026.103247_bib16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12879-022-07068-0","article-title":"Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials","volume":"22","author":"Vegivinti","year":"2022","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.jiph.2026.103247_bib17","article-title":"Temporal trends in test-seeking behaviour during the COVID-19 pandemic","volume":"2","author":"Eales","year":"2025","journal-title":"Math Med Life Sci"},{"key":"10.1016\/j.jiph.2026.103247_bib18","unstructured":"Victorian Healthcare Associated Infection Surveillance Coordinating Centre (VICNISS). Healthcare-associated infections in Victoria: Surveillance report 2022-23. 2024 [cited 27 November 2025] Available from: \u3008https:\/\/www.vicniss.org.au\/media\/0d0j0upr\/vicnissannualreport2022_23_final_feb2024.pdf\u3009]."},{"key":"10.1016\/j.jiph.2026.103247_bib19","unstructured":"Victorian Healthcare Associated Infection Surveillance Coordinating Centre (VICNISS). Healthcare-associated infections in Victoria: Surveillance report 2021-22. 2023 [cited 27 November 2025] Available from: \u3008https:\/\/www.vicniss.org.au\/media\/f5zif1yx\/rfq07746-pdi-vicniss-annualreport2022_a4march2023.pdf\u3009]."},{"key":"10.1016\/j.jiph.2026.103247_bib20","article-title":"Mandatory testing to end along with forced COVID-19 isolation","author":"Lucas","year":"2022","journal-title":"Age"},{"key":"10.1016\/j.jiph.2026.103247_bib21","unstructured":"Department of Health, Disability and Ageing, Australian Government. Coronavirus Disease 2019 (COVID-19) \u2013 Surveillance case definition. 2024 [cited 27 November 2025] Available from: \u3008https:\/\/www.health.gov.au\/resources\/publications\/coronavirus-disease-2019-covid-19-surveillance-case-definition?language=en\u3009]."}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187603412600119X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187603412600119X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T12:06:39Z","timestamp":1781697999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187603412600119X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S187603412600119X"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2026.103247","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Measuring oral COVID-19 antiviral effectiveness using linked Australian data: Challenges and opportunities","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2026.103247","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}],"article-number":"103247"}}